Mary Crowley Cancer Research: Comprehensive Company Profile

Background

Overview

Mary Crowley Cancer Research is a non-profit 501(c)(3) organization established in 1997, dedicated to advancing cancer treatment through innovative clinical trials. Operating in compliance with FDA guidelines for over two decades, the center focuses on personalized medicine, aligning individual patients' cancers with the latest discoveries in gene and immune-based therapies.

Mission and Vision

The mission of Mary Crowley Cancer Research is to bring hope to cancer patients by providing access to cutting-edge therapies and advancing global treatment options. The vision is to rapidly advance the discovery of potential new therapies, positively impacting cancer care in patients' lifetimes.

Primary Area of Focus

The center specializes in early-phase clinical trials, particularly Phase I and II, offering patients access to investigational therapies that are not yet widely available. This approach emphasizes personalized treatment plans based on the molecular characteristics of each patient's cancer.

Industry Significance

Mary Crowley Cancer Research has been instrumental in the development of numerous FDA-approved cancer therapies, contributing significantly to the advancement of personalized medicine in oncology. Its focus on early-phase trials positions it as a leader in translating laboratory discoveries into clinical applications.

Key Strategic Focus

Core Objectives

• Personalized Medicine: Tailoring cancer treatments to the individual genetic profiles of patients to enhance efficacy and minimize side effects.

• Early-Phase Clinical Trials: Conducting Phase I and II trials to evaluate the safety and efficacy of new therapies.

• Global Impact: Advancing cancer treatment options worldwide by rapidly translating research findings into clinical practice.

Specific Areas of Specialization

• Gene Therapy: Utilizing genetic material to treat or prevent cancer.

• Immunotherapy: Harnessing the body's immune system to fight cancer cells.

• Vaccine Therapy: Developing vaccines that stimulate the immune system to attack cancer cells.

Key Technologies Utilized

• Genomic Sequencing: Analyzing patients' genetic information to identify potential targets for therapy.

• Biomarker Identification: Detecting specific molecules that indicate the presence or progression of cancer.

• Clinical Trial Management Systems: Implementing advanced systems to efficiently manage and monitor clinical trials.

Primary Markets or Conditions Targeted

Mary Crowley Cancer Research focuses on a broad spectrum of adult solid tumors, including but not limited to breast, lung, colorectal, and pancreatic cancers. Additionally, the center has extended its research to include pediatric cancers, such as Ewing's Sarcoma.

Financials and Funding

Funding History

As a non-profit organization, Mary Crowley Cancer Research relies on a combination of private donations, grants, and partnerships to fund its operations. In 2024, the center reported total revenues of $20,603,348 and expenses of $17,107,470, with total assets amounting to $24,324,731.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly disclosed. However, the center has consistently secured funding through various channels, including private donations and grants from foundations and other non-profits.

Notable Investors

While individual donors are not publicly listed, the center has received significant support from organizations such as the Be the Difference Foundation, which has provided grants to support clinical trials and patient services.

Intended Utilization of Capital

Funds are primarily allocated towards conducting clinical trials, patient services, research operations, and expanding the center's capabilities to offer innovative cancer treatments. A portion of the capital is also directed towards community outreach and educational programs to raise awareness about clinical trial opportunities.

Pipeline Development

Key Pipeline Candidates

Mary Crowley Cancer Research is involved in numerous early-phase clinical trials, focusing on:

• Targeted Therapies: Drugs designed to specifically attack cancer cells based on genetic markers.

• Immunotherapies: Treatments that stimulate the immune system to recognize and destroy cancer cells.

• Vaccine Therapies: Vaccines aimed at eliciting an immune response against cancer-specific antigens.

Stages of Clinical Trials or Product Development

The center primarily conducts Phase I and II clinical trials, assessing the safety, dosage, and efficacy of new treatments. These trials are often in collaboration with pharmaceutical companies and academic institutions.

Target Conditions

The trials target a wide range of cancers, including:

• Solid Tumors: Such as breast, lung, colorectal, and pancreatic cancers.

• Pediatric Cancers: Including Ewing's Sarcoma.

Relevant Timelines for Anticipated Milestones

Specific timelines for trial milestones are typically outlined in individual study protocols and are subject to regulatory approvals and patient enrollment rates.

Technological Platform and Innovation

Proprietary Technologies

• Genospace: A personalized medicine platform that transforms patient data into actionable insights for treatment.

Significant Scientific Methods

• Genomic Sequencing: Utilized to identify genetic mutations and biomarkers associated with cancer.

• Biomarker Analysis: Employed to predict patient responses to specific therapies.

• Clinical Trial Management Systems: Advanced systems used to streamline trial operations and data collection.

Leadership Team

Key Executive Profiles

• Jennifer Fox: Chief Executive Officer. Jennifer has been with Mary Crowley Cancer Research for several years, leading the organization in its mission to provide innovative cancer treatments.

• Minal Barve: Executive Medical Director. Dr. Barve oversees the clinical operations and research initiatives, ensuring the center's trials meet the highest standards.

• James F. Strauss: Physician Investigator. Dr. Strauss contributes to the design and implementation of clinical trials, focusing on advancing cancer therapies.

• Jennifer Hunter: Director of Research Operations. Jennifer manages the day-to-day operations of the research department, facilitating efficient trial execution.

• Nancy Parks: Accounting Manager. Nancy oversees the financial operations, ensuring fiscal responsibility and transparency.

Leadership Changes

In October 2022, Edward Marx and Rodney Olsen were appointed to the Board of Directors, bringing expertise in digital transformation and financial management, respectively.

Competitor Profile

Market Insights and Dynamics

The oncology clinical trial market is characterized by rapid innovation, with a growing emphasis on personalized medicine and immunotherapies. There is an increasing demand for early-phase clinical trials to evaluate novel treatments.

Competitor Analysis

• Sarah Cannon Research Institute (SCRI): A leading oncology research organization conducting community-based clinical trials. In January 2025, SCRI expanded its network by acquiring Mary Crowley Cancer Research, enhancing its capabilities in early-phase research.

• Massive Bio: Develops AI-driven platforms for cancer treatments, focusing on matching patients with appropriate clinical trials.

• ZenOncoIO: An integrative oncology healthtech platform offering personalized cancer care solutions.

• VieCure: Provides an AI-based clinical decision support platform in oncology, aiding in treatment planning.

• Valar Labs: Develops an AI platform for oncologists, enhancing clinical decision-making processes.

Strategic Collaborations and Partnerships

• Sarah Cannon Research Institute: Acquired Mary Crowley Cancer Research in January 2025, expanding its early-phase research capabilities.

• The WiTT Group: Partnered to enhance access to clinical trials for underserved and low-income cancer patients.